- ISPOR 2020
- ISPOR Asia Pacific 2020
- ISPOR Europe 2020
- ISPOR-FDA Summit 2020
- ISPOR Europe 2019
- ISPOR Summit 2019
- ISPOR Latin America Summit 2019
- ISPOR Latin America 2019
- ISPOR 2019
- ISPOR Warsaw 2019
- ISPOR Europe 2018
- ISPOR Summit 2018
- ISPOR Dubai 2018
- ISPOR Asia Pacific 2018
- ISPOR 2018
- ISPOR Europe 2017
- ISPOR Latin America 2017
- ISPOR Asia Pacific 2016
- Abstract Information
- Submit Abstract
- Exhibits & Sponsorships
- Awards & Grants
- Recent Conferences
- Upcoming Conferences
Education & Training
- Short Courses
- Economic evaluation of vaccination programs
- Patient-Preference Information – What It Is and What It Is Not
- 2020 Top 10 HEOR Trends
- Adding Depth to Observational Research through Data Linkage
- New Developments of Health Technology Assessment in Asia Pacific
- Financing Epidemics: Developing an Insurance Scheme for Outbreaks in Africa
- Why and How to Use Qualitative Research Methods in Conjunction with Discrete Choice Experiments in Healthcare
- Health Technology Assessment Training
This webinar has already passed. You can view the recording here.
- Michelle Tarver, MD, PhD
- Deborah A Marshall, PhD
- Brett Hauber, PhD
This webinar will provide a background on patient-preference methods and conducting patient-preference studies. The topics covered will include overviews of (1) what patient-preference information (PPI) is and what it is not, (2) a range of stated-preference methods, (3) the core components in the design of a stated-preference study, and (4) the recommended qualities of patient-preference studies that are outlined in FDA’s PPI guidance. In addition, the presenters will use an example of a stated-preference study to elucidate some of the concepts addressed in the webinar.
This will serve as an introduction for those who may be less familiar with methods for eliciting PPI and those for whom an overview of methods would be valuable prior to the upcoming ISPOR-FDA Summit 2020 on “Using Patient-Preference Information in Medical Device Regulatory Decisions: Benefit-Risk and Beyond.” The Summit will address issues related to the development and use of PPI in multiple decisions faced by FDA and other stakeholders.
All are invited to attend the webinar (including those registered and not registered for the Summit).
After attending this webinar participants will be able to:
- Explain the range of methods that are included among stated-preference methods;
- Discuss the difference between patient-preference information and other types of input;
- Identify the core components in designing and implementing a stated-preference project; and
- Recognize the recommended qualities of patient preference studies considered when determining whether PPI constitutes valid scientific evidence.
This webinar is open to All ISPOR Members and Non-members.
Michelle Tarver, MD, PhD
Director, Patient Science & Engagement Program
Center for Devices and Radiological Health (CDRH)
Office of Strategic Partnerships and Technology Innovation (OST)
Division of All Hazards Response, Science and Strategic Partnerships (DARSS)
U.S. Food and Drug Administration (FDA)
Silver Spring, MD, USA
Deborah A Marshall, PhD
University of Calgary
Calgary, AB, Canada
A. Brett Hauber, PhD
Senior Economist & Vice President
Health Preference Assessment
RTI Health Solutions
Research Triangle Park, NC, USA
Please note: On the day of the scheduled webinar, the first 500 registered participants will be accepted into the webinar. For those who are unable to attend, or would like to review the webinar at a later date, the full-length webinar recording will be made available at the ISPOR Educational Webinar Series webpage approximately 2 weeks after the scheduled Webinar.
Reservations are on a first-come, first-served basis for all ISPOR members.